News : Olerup SSP

LinkMed’s transplantation company, Olerup SSP, has signed an exclusive sales agreement with the American company Biotium for their product GelRed™. The sales agreements gives Olerup SSP the exclusive rights to sell GelRed™ to the HLA typing market. GelRed™ is an environmentally safe and ultrasensitive fluorescent nucleic acid gel stains designed to replace the highly toxic ethidium bromide (EtBr).

The Board of Directors of LinkMed today announced a strategic decision to further focus the company’s operations on the transplantation sector. Consequently, LinkMed will work actively to find additional acquisitions in the sector and continue its global efforts in Olerup SSPs and AbSorber’s product area. Going forward, LinkMed will prioritize investment in this sector. At the same time, the company will intensify...

Olerup SSP, a wholly owned subsidiary of LinkMed, has had its Taq-polymerase-free HLA typing kit registered and cleared by the FDA. This means that Olerup SSP’s entire product range for HLA typing, with or without Taq polymerase, can now be marketed and sold to a greater number of healthcare centers in North America. The U.S. is the single largest market for HLA typing and represents over 40 percent of the global...